Progress of chimeric antigen receptor T-cell therapy for multiple myeloma
10.3760/cma.j.cn115356-20191220-00265
- VernacularTitle:多发性骨髓瘤嵌合抗原受体T细胞治疗研究进展
- Author:
Quande LIN
1
;
Yan YAN
;
Yongping SONG
Author Information
1. 郑州大学附属肿瘤医院 河南省肿瘤医院血液科 450003
- From:
Journal of Leukemia & Lymphoma
2020;29(3):136-140
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T-cell (CAR-T) therapy has made a breakthrough in the treatment of hematological tumors. CAR-T therapy targeting kappa immunoglobulin light chain, CD19 and B-cell mature antigen (BCMA) have been used to treat relapsed/refractory MM (RRMM) patients, and the effect of anti-BCMA CAR-T is the best. However, the negative or positive recurrence of BCMA leads to a short progression-free survival (PFS), the improvement of the chimeric antigen receptor (CAR) structure targeted BCMA, dual-targeted CAR-T and CAR-T combined with small molecular drugs as well as other measures have become the focuses of CAR-T in the treatment of RRMM.
